And colleagues from All India Institute of Medical Sciences, New Delhi, India, randomly allocated 49 patients with moderate-to-severe OLP to receive either oral betamethasone on 2 consecutive days per week (n=25) or triamcinolone acetonide (0.Times per day (n=24), for 3 months followed by stepwise tapering during the subsequent 3 months.Months of therapy, 68% of patients treated with betamethasone and 66% of patients receiving triamcinolone acetonide achieved a good to excellent objective response, defined as a 50-75% and >75% reduction in the clinical score, respectively.Therapeutic response was demonstrated with betamethasone, at a median of 15.With 19.For triamcinolone acetonide.From baseline in the mean clinical scores was significant from week 4 onwards in the betamethasone group and from week 8 onwards in the triamcinolone acetonide group.To betamethasone OMP therapy was most pronounced in patients with erosive disease.11 of those receiving betamethasone and five of those receiving triamcinolone acetonide, the improvement from baseline in the mean clinical scores was significant from 2 and 12 weeks onwards, respectively.Reversible adverse events were reported in 56% and 25% of patients in the betamethasone and triamcinolone acetonide groups, respectively.Of patients treated with betamethasone and 21.Receiving triamcinolone acetonide relapsed after a mean period of 13.19.Respectively.The result of fast tapering of corticosteroid dose after 3 months of OMP therapy, write Khaitan and colleagues in the _Journal of the American Academy of Dermatology_, who note that their study "does not ascertain the ability of OMP regimen in achieving long-lasting remissions.Read more Inhaled insulin loses support
Get more [medical_sciences] overexpression of the dual-specificity phosphatase mkp-4/dusp-9 protects against stress-induced insulin resistance
